COVID-19 Diagnostics Market 2022 Growth Drivers, Regional Outlook, Competitive Strategies and Forecast up to 2026

News provided by

Shibuya Data Count

Jan 02, 2022, 23:22 EST

Shibuya-ku, Tokyo, Japan, Japan, Jan 02, 2022, 23:22 /Comserve / -- The global COVID-19 diagnostics market by revenue is expected to register a negative CAGR of (9%) during the period 2021–2026.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global COVID-19 Diagnostics Market Report

The global COVID-19 diagnostics market by revenue is expected to register a negative CAGR of (9%) during the period 2021–2026.

The RT-PCR testing segment constituted over 75% of the global COVID diagnostics market share. The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing. The adoption of a population-wide testing approach, which includes household, individual testing, is one of the trends influencing the demand for covid-19 diagnostics kits. The shift from symptomatic testing to mass testing in developed countries is another major factor affecting the market.

Request For PDF Sample Copy:-

The following factors are likely to contribute to the growth of the COVID-19 diagnostics market during the forecast period:
• Increased Demand for Mass Testing
• Demand for Molecular Diagnostics due to Covid-19 Pandemic
• Unavailability of Specific Medicines/ Vaccines

The study considers the present scenario of the COVID-19 diagnostics market and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Global Covid-19 Diagnostics Market Segmentation
This research report includes a detailed segmentation by product, end-users, test, technology, geography. In 2020, the consumables segment constituted over 74% of the global COVID-19 diagnostics market share. The demand for consumables, including biomarkers and reagents, including substrates, enzymes, electrolytes, specific proteins, lipids, and point-of-care test kits, is growing as they obtain quick and accurate results for diagnosing diseases, including COVID-19. The need to perform rapid testing to detect coronavirus spread across the world is driving the demand for consumables.

As RT-PCR testing is considered exceptionally reliable, the segment constituted over 75% of the global COVID diagnostics market share. The market is witnessing an increasing uptake of PCR testing to deliver a reliable diagnosis in quick succession. Currently, the reverse transcription-polymerase chain reaction (RT-PCR) is a standard for diagnosing COVID-19. With the WHO recommending PCR testing as one of the reliable methods for COVID-19 test procedures, countries such as the US, Brazil, Russia, India, Germany, Italy, and Spain drive the demand for PCR kits the virus highly infects these regions. Antigen and antibody testing accounted for a small share of the global COVID-19 diagnostics market. These tests are considered an important factor in mass screening. However, due to a lack of specificity and sensitivity, these tests were not initially used in several countries. As the COVID-19 pandemic continues, vendors came up with advanced antibody and antigen tests, driving the market growth.

The failure of several rapid diagnostics kits to detect the presence of the COVID-19 virus in several countries has led to the development of molecular-based-PCR testing for covid-19 diagnosis. The share of molecular diagnostic test makers has increased drastically, with the WHO declaring RT-PCR as the standard test for Covid-19 diagnosis. This trend is followed in several developed, developing, and underdeveloped countries, thereby generating a high demand for molecular diagnostic testing. The immunoassay segment accounted for over 24% of the global market share in 2020. These tests are conducted on those with maximum exposure to the covid-19 virus, especially healthcare professionals and medical practitioners.

In most countries, diagnostic laboratories, which include standard and public health laboratories, have played a significant role in detecting covid-19. The demand for standalone laboratories is growing gradually owing to the prevalence of pandemic, epidemic conditions, or the outbreak of unexpected infectious diseases, requiring immediate diagnosis of the diseases for a large population in a shorter time. Hospitals have played a major role in covid-19 testing since its outbreak. A majority of hospitals have their own in-house laboratories to conduct diagnostic tests, which help them to admit and monitor COVID-19 patients. Hence the segment is witnessing a high demand for COVID-19 testing kits. The demand for COVID-19 diagnostic kits from ambulatory care settings increased in developed countries as these settings accommodated several asymptomatic patients.

By Product
• Consumables
• Analyzers/Instruments
By Test
• Antigen
• Antibody
By Technology
• Molecular
• Immunology
By End-user
• Laboratories
• Hospitals
• Ambulatory Care Settings
• Research Institutes

APAC emerged as the largest Covid-19 diagnostics market and is likely to retain its position during the forecast year due to the widespread COVID infection in the population. Several countries in the region, especially India, where the number of people infected with coronavirus stood at 8.5 million in October 2020, are likely to increase mass testing, thereby increasing the demand. The presence of a large population, poor living standards, and inadequate medical infrastructure are the major factors responsible for the infection's high prevalence. However, increased mass testing initiatives and high investments in public healthcare services are likely to favor the COVID-19 diagnostics testing market. China, Japan, India, South Korea, and Australia are the major revenue contributors to the APAC COVID-19 diagnostics market. Several countries preferred using PCR-based testing due to their higher accuracy than serological tests. Australia and New Zealand have increased their testing capacities to reduce the impact of the disease.

By Geography
• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Russia
o China
o Japan
o South Korea
o Australia
o India
o Indonesia
o Philippines
• Latin America
o Brazil
o Mexico
o Argentina
o Peru
o Colombia
o Chile
• Middle East & Africa
o Saudi Arabia
o South Africa
o Turkey
o Iran

The global coronavirus diagnostics market is highly dynamic with the presence of several global, regional, and local company profiles, offering a diverse range of analyzers, test kits, assays, and reagents to perform COVID-19 tests. Abbott, BD, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are the major player in the diagnostics market. Global market players focus on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio.

Prominent Vendors
• Abbott
• Siemens Healthineers
• Hoffmann-La Roche
• Thermo Fisher Scientific
• Danaher
• BD

Other Prominent Vendors
• Abingdon Health
• Assure Tech. (Hangzhou)
• Autobio Diagnostics
• Advaite
• Babson Diagnostics
• Beijing Wantai Biological
• Biomerica
• bioMérieux
• Biopanda Reagents
• Biocerna
• Biocan Diagnostics
• BioMedomics
• Clinical Reference Laboratory
• Cellex
• The Center for Chest Diseases and Prevention (CDC)
• CTK Biotech
• DiaSorin
• Diazyme Laboratories
• Erba Mannheim
• Edinburgh Genetics
• Eurofins Scientific
• GenScript
• Healgen Scientific
• Hangzhou AllTest Biotech
• Hangzhou Biotest Biotech
• Jiangsu Well Biotech
• Kabla Diagnostics
• Luminex
• Meridian Bioscience
• Megna Health
• Microgen
• MP Biomedicals
• Nova Tech Immunodiagnostica
• NOWDiagnostics
• Quotient
• Quidel
• Sekisui Diagnostics
• Sinocare
• SureScreen Diagnostics
• Salofy Oy
• Shenzhen New Industries Biomedical Engineering (SNIBE)
• Sysmex
• Vibrant America
• Warrior Diagnostics
• Xiamen Biotime Biotechnology
• Zuhai Livzon Diagnostic

Request For PDF Sample Copy:-

1. What is the total market value of the COVID-19 Diagnostics Market report?
2. Which test type accounted for the largest COVID-19 diagnostics market share?
3. Will COVID-19 testing demand drive the global point-of-care testing market?
4. What factors could help to bridge the supply-chain gap in the market?
5. Which are the key perspectives that key vendors are leveraging to move businesses to a new growth trajectory?
6. What are some of the potential barriers for the existing players in the market?

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Lauren Brown

Shibuya Data Count
Tel: + 81 50 50509159

Related Links